# Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

> **NCT00753272** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 43695 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GSK Bio's influenza vaccine GSK2186877A
- **BIOLOGICAL:** Fluarix TM

## Key facts

- **NCT ID:** NCT00753272
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-15
- **Primary completion:** 2010-06-18
- **Final completion:** 2011-01-05
- **Target enrollment:** 43695 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753272, "Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00753272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*